Wall Street Zen Downgrades Keros Therapeutics (NASDAQ:KROS) to Strong Sell

Keros Therapeutics (NASDAQ:KROS) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday, Wall Street Zen reports.

Other research analysts have also issued reports about the stock. Zacks Research upgraded shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Leerink Partners dropped their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.50.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $11.32 on Friday. The company has a market cap of $224.48 million, a P/E ratio of -3.06 and a beta of 1.01. The business has a fifty day simple moving average of $10.81 and a 200-day simple moving average of $11.37. Keros Therapeutics has a 52 week low of $9.69 and a 52 week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Sell-side analysts expect that Keros Therapeutics will post -5.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Keros Therapeutics

In other news, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the transaction, the insider directly owned 27,559 shares of the company’s stock, valued at $283,582.11. The trade was a 11.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 5,893 shares of company stock valued at $60,507. Insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd grew its stake in Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after buying an additional 1,166 shares during the period. California State Teachers Retirement System raised its stake in shares of Keros Therapeutics by 72.6% in the 2nd quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock valued at $29,000 after acquiring an additional 1,148 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares during the period. Legal & General Group Plc acquired a new position in shares of Keros Therapeutics during the 2nd quarter valued at $90,000. Finally, XTX Topco Ltd purchased a new stake in Keros Therapeutics during the 4th quarter worth $212,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.